- Home
- FLNC vs ARDX Comparison
FLNC vs ARDX Comparison
Compare FLNC & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNC
- ARDX
- Stock Information
- Founded
- FLNC 2018
- ARDX 2007
- Country
- FLNC United States
- ARDX United States
- Employees
- FLNC N/A
- ARDX N/A
- Industry
- FLNC Industrial Machinery/Components
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- FLNC Miscellaneous
- ARDX Health Care
- Exchange
- FLNC Nasdaq
- ARDX Nasdaq
- Market Cap
- FLNC 802.6M
- ARDX 882.9M
- IPO Year
- FLNC 2021
- ARDX 2014
- Fundamental
- Price
- FLNC $7.78
- ARDX $4.33
- Analyst Decision
- FLNC Hold
- ARDX Strong Buy
- Analyst Count
- FLNC 18
- ARDX 9
- Target Price
- FLNC $8.38
- ARDX $10.17
- AVG Volume (30 Days)
- FLNC 4.7M
- ARDX 4.0M
- Earning Date
- FLNC 08-11-2025
- ARDX 08-04-2025
- Dividend Yield
- FLNC N/A
- ARDX N/A
- EPS Growth
- FLNC N/A
- ARDX N/A
- EPS
- FLNC N/A
- ARDX N/A
- Revenue
- FLNC $2,329,871,000.00
- ARDX $361,706,000.00
- Revenue This Year
- FLNC $2.98
- ARDX $10.10
- Revenue Next Year
- FLNC $25.19
- ARDX $32.38
- P/E Ratio
- FLNC N/A
- ARDX N/A
- Revenue Growth
- FLNC 6.08
- ARDX 127.33
- 52 Week Low
- FLNC $3.46
- ARDX $3.21
- 52 Week High
- FLNC $24.00
- ARDX $7.18
- Technical
- Relative Strength Index (RSI)
- FLNC 47.07
- ARDX 52.98
- Support Level
- FLNC $8.16
- ARDX $4.21
- Resistance Level
- FLNC $9.53
- ARDX $4.47
- Average True Range (ATR)
- FLNC 0.52
- ARDX 0.18
- MACD
- FLNC -0.26
- ARDX -0.04
- Stochastic Oscillator
- FLNC 5.18
- ARDX 41.46
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.